Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Par Acquisition By TPG Allows Competing Marriage Proposals

This article was originally published in The Pink Sheet Daily

Executive Summary

Par will be acquired by private equity firm TPG in $1.9 billion deal if no other suitors come forward with a better offer over the next month.

You may also be interested in...



Deal Watch: Endo Hopes To Boost Generics Unit With Buy-Out Of Par

J&J is teaming with Achillion to produce a combo regimen for hepatitis C that might compete with offerings from Gilead, AbbVie and Merck. Amgen is dropping out of its collaboration on brodalumab with AstraZeneca due to concerns about suicidality in clinical trials.

Endo Continues To Expand Generics Business With Par Acquisition

After losing out on Salix to competitor Valeant, Endo makes a strong move into sterile injectables and other alternative dosage forms, and positions itself as the No. 5 generics firm in the U.S.

Par Enters Generic Injectable Market Via JHP Buy

The generics maker is expanding its portfolio of reformulations through the acquisition of privately-held JHP in a deal worth $490 million, expected to close in short order.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074385

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel